Antiviral activity, dose–response relationship, and safety of entecavir following 24-week oral dosing in nucleoside-naive Japanese adult patients with chronic hepatitis B: a randomized, double-blind, phase II clinical trial
暂无分享,去创建一个
N. Hayashi | K. Chayama | M. Sata | O. Yokosuka | T. Okanoue | J. Toyota | M. Omata | H. Tsubouchi | Kazuyuki Suzuki | H. Kumada | T. Seriu | S. Mochida | E. Tomita | H. Ishikawa | M. Shindo